High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau
This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Affiliated Hospital of Qinghai University Academic / other |
| Locations | 1 site (Xining, Qinghai) |
| Trial ID | NCT07205523 on ClinicalTrials.gov |
What this trial studies
HALO-SCT is a prospective observational registry based at the Affiliated Hospital of Qinghai University that enrolls patients undergoing hematopoietic stem cell transplantation and their donors. The registry captures demographic, diagnostic, treatment, outcome, and health‑resource data and incorporates historical cases alongside ongoing prospective follow-up. Biospecimens including peripheral blood and bone marrow are collected at baseline and follow-up for future multi‑omics analyses. No experimental treatments are mandated and all clinical care follows routine practice while data are used to build long‑term research infrastructure and support collaborations.
Who should consider this trial
Good fit: Ideal participants are people with hematologic diseases who are planning or undergoing hematopoietic stem cell transplantation at the Qinghai University Affiliated Hospital on or after September 1, 2023 and who can give informed consent and complete follow‑up.
Not a fit: Patients unlikely to benefit include those who cannot provide long‑term follow‑up due to severe comorbidities or logistical barriers, those with active substance abuse compromising adherence, or those judged unsafe or noncompliant by investigators.
Why it matters
Potential benefit: If successful, the registry could improve understanding of how high altitude influences transplant complications, survival, and immune recovery, leading to better counseling and care plans for patients in plateau regions.
How similar studies have performed: This registry is the first prospective HSCT cohort specific to the Qinghai‑Tibet Plateau, though national and international HSCT registries elsewhere have successfully informed practice and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed informed consent. Exclusion Criteria: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance.
Where this trial is running
Xining, Qinghai
- Affiliated Hospital of Qinghai University — Xining, Qinghai, China (Recruiting)
Study contacts
- Principal investigator: Hui Geng — Affiliated Hospital of Qinghai University
- Study coordinator: Yigeng CAO, MD,PhD
- Email: caoyigeng@ihcams.ac.cn
- Phone: +8618622477066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.